Cargando…

Baseline Serum HE4 But Not Tissue HE4 Expression Predicts Response to the Levonorgestrel-Releasing Intrauterine System in Atypical Hyperplasia and Early Stage Endometrial Cancer

The levonorgestrel-releasing intrauterine system (LNG-IUS) is a conservative management option for atypical hyperplasia (AH) and low grade early stage endometrial cancer (EEC), but around 1 in 3 patients fail to respond to treatment. The aim of this study was to investigate if serum and/or tissue HE...

Descripción completa

Detalles Bibliográficos
Autores principales: Behrouzi, Roya, Ryan, Neil A. J., Barr, Chloe E., Derbyshire, Abigail E., Wan, Y. Louise, Maskell, Zoe, Stocking, Katie, Pemberton, Philip W., Bolton, James, McVey, Rhona J., Crosbie, Emma J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7073190/
https://www.ncbi.nlm.nih.gov/pubmed/31979212
http://dx.doi.org/10.3390/cancers12020276
_version_ 1783506580833042432
author Behrouzi, Roya
Ryan, Neil A. J.
Barr, Chloe E.
Derbyshire, Abigail E.
Wan, Y. Louise
Maskell, Zoe
Stocking, Katie
Pemberton, Philip W.
Bolton, James
McVey, Rhona J.
Crosbie, Emma J.
author_facet Behrouzi, Roya
Ryan, Neil A. J.
Barr, Chloe E.
Derbyshire, Abigail E.
Wan, Y. Louise
Maskell, Zoe
Stocking, Katie
Pemberton, Philip W.
Bolton, James
McVey, Rhona J.
Crosbie, Emma J.
author_sort Behrouzi, Roya
collection PubMed
description The levonorgestrel-releasing intrauterine system (LNG-IUS) is a conservative management option for atypical hyperplasia (AH) and low grade early stage endometrial cancer (EEC), but around 1 in 3 patients fail to respond to treatment. The aim of this study was to investigate if serum and/or tissue HE4 expression could predict response to LNG-IUS therapy. Patients with AH or presumed Stage I EEC had serum and endometrial samples taken at baseline and at 3-month intervals over 12 months post-insertion of LNG-IUS. 74 patients were recruited and baseline demographics recorded. Of 57 patients for whom response was histologically determinable, 39 (68%) were responders and 18 (32%) non-responders. Mean baseline serum HE4 was significantly lower in responders (62.1 ± 1.1 pM, 95% confidence interval (CI) 52.7–73.2), compared to non-responders (125.6 ± 1.3 pM, 95% CI 74.5–211.7, p = 0.014), including when considering age, BMI, menopausal status, smoking status, and histological grade as covariables (p = 0.005). Baseline tissue HE4 expression was not significantly different in responders compared to non-responders (p = 0.999). Responders showed a significant mean reduction (−9.8 ± 3.4%, 95% CI −16.7 to −2.8%, p = 0.008) in serum HE4 between baseline and 3 months (p = 0.008), whereas non-responders showed no significant change (p = 0.676). Neither responders nor non-responders showed a significant percentage change in serum HE4 from baseline beyond 3 months (p > 0.05). Change in serum HE4 between baseline and 3 and 6 months and tissue HE4 tissue expression between baseline and 3, 6, and 12 months was not significantly different in responders compared to non-responders (p > 0.05). This study suggests that baseline serum HE4, but not baseline tissue HE4 expression, is independently predictive of response to the LNG-IUS and could be used to guide management decisions.
format Online
Article
Text
id pubmed-7073190
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-70731902020-03-19 Baseline Serum HE4 But Not Tissue HE4 Expression Predicts Response to the Levonorgestrel-Releasing Intrauterine System in Atypical Hyperplasia and Early Stage Endometrial Cancer Behrouzi, Roya Ryan, Neil A. J. Barr, Chloe E. Derbyshire, Abigail E. Wan, Y. Louise Maskell, Zoe Stocking, Katie Pemberton, Philip W. Bolton, James McVey, Rhona J. Crosbie, Emma J. Cancers (Basel) Article The levonorgestrel-releasing intrauterine system (LNG-IUS) is a conservative management option for atypical hyperplasia (AH) and low grade early stage endometrial cancer (EEC), but around 1 in 3 patients fail to respond to treatment. The aim of this study was to investigate if serum and/or tissue HE4 expression could predict response to LNG-IUS therapy. Patients with AH or presumed Stage I EEC had serum and endometrial samples taken at baseline and at 3-month intervals over 12 months post-insertion of LNG-IUS. 74 patients were recruited and baseline demographics recorded. Of 57 patients for whom response was histologically determinable, 39 (68%) were responders and 18 (32%) non-responders. Mean baseline serum HE4 was significantly lower in responders (62.1 ± 1.1 pM, 95% confidence interval (CI) 52.7–73.2), compared to non-responders (125.6 ± 1.3 pM, 95% CI 74.5–211.7, p = 0.014), including when considering age, BMI, menopausal status, smoking status, and histological grade as covariables (p = 0.005). Baseline tissue HE4 expression was not significantly different in responders compared to non-responders (p = 0.999). Responders showed a significant mean reduction (−9.8 ± 3.4%, 95% CI −16.7 to −2.8%, p = 0.008) in serum HE4 between baseline and 3 months (p = 0.008), whereas non-responders showed no significant change (p = 0.676). Neither responders nor non-responders showed a significant percentage change in serum HE4 from baseline beyond 3 months (p > 0.05). Change in serum HE4 between baseline and 3 and 6 months and tissue HE4 tissue expression between baseline and 3, 6, and 12 months was not significantly different in responders compared to non-responders (p > 0.05). This study suggests that baseline serum HE4, but not baseline tissue HE4 expression, is independently predictive of response to the LNG-IUS and could be used to guide management decisions. MDPI 2020-01-23 /pmc/articles/PMC7073190/ /pubmed/31979212 http://dx.doi.org/10.3390/cancers12020276 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Behrouzi, Roya
Ryan, Neil A. J.
Barr, Chloe E.
Derbyshire, Abigail E.
Wan, Y. Louise
Maskell, Zoe
Stocking, Katie
Pemberton, Philip W.
Bolton, James
McVey, Rhona J.
Crosbie, Emma J.
Baseline Serum HE4 But Not Tissue HE4 Expression Predicts Response to the Levonorgestrel-Releasing Intrauterine System in Atypical Hyperplasia and Early Stage Endometrial Cancer
title Baseline Serum HE4 But Not Tissue HE4 Expression Predicts Response to the Levonorgestrel-Releasing Intrauterine System in Atypical Hyperplasia and Early Stage Endometrial Cancer
title_full Baseline Serum HE4 But Not Tissue HE4 Expression Predicts Response to the Levonorgestrel-Releasing Intrauterine System in Atypical Hyperplasia and Early Stage Endometrial Cancer
title_fullStr Baseline Serum HE4 But Not Tissue HE4 Expression Predicts Response to the Levonorgestrel-Releasing Intrauterine System in Atypical Hyperplasia and Early Stage Endometrial Cancer
title_full_unstemmed Baseline Serum HE4 But Not Tissue HE4 Expression Predicts Response to the Levonorgestrel-Releasing Intrauterine System in Atypical Hyperplasia and Early Stage Endometrial Cancer
title_short Baseline Serum HE4 But Not Tissue HE4 Expression Predicts Response to the Levonorgestrel-Releasing Intrauterine System in Atypical Hyperplasia and Early Stage Endometrial Cancer
title_sort baseline serum he4 but not tissue he4 expression predicts response to the levonorgestrel-releasing intrauterine system in atypical hyperplasia and early stage endometrial cancer
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7073190/
https://www.ncbi.nlm.nih.gov/pubmed/31979212
http://dx.doi.org/10.3390/cancers12020276
work_keys_str_mv AT behrouziroya baselineserumhe4butnottissuehe4expressionpredictsresponsetothelevonorgestrelreleasingintrauterinesysteminatypicalhyperplasiaandearlystageendometrialcancer
AT ryanneilaj baselineserumhe4butnottissuehe4expressionpredictsresponsetothelevonorgestrelreleasingintrauterinesysteminatypicalhyperplasiaandearlystageendometrialcancer
AT barrchloee baselineserumhe4butnottissuehe4expressionpredictsresponsetothelevonorgestrelreleasingintrauterinesysteminatypicalhyperplasiaandearlystageendometrialcancer
AT derbyshireabigaile baselineserumhe4butnottissuehe4expressionpredictsresponsetothelevonorgestrelreleasingintrauterinesysteminatypicalhyperplasiaandearlystageendometrialcancer
AT wanylouise baselineserumhe4butnottissuehe4expressionpredictsresponsetothelevonorgestrelreleasingintrauterinesysteminatypicalhyperplasiaandearlystageendometrialcancer
AT maskellzoe baselineserumhe4butnottissuehe4expressionpredictsresponsetothelevonorgestrelreleasingintrauterinesysteminatypicalhyperplasiaandearlystageendometrialcancer
AT stockingkatie baselineserumhe4butnottissuehe4expressionpredictsresponsetothelevonorgestrelreleasingintrauterinesysteminatypicalhyperplasiaandearlystageendometrialcancer
AT pembertonphilipw baselineserumhe4butnottissuehe4expressionpredictsresponsetothelevonorgestrelreleasingintrauterinesysteminatypicalhyperplasiaandearlystageendometrialcancer
AT boltonjames baselineserumhe4butnottissuehe4expressionpredictsresponsetothelevonorgestrelreleasingintrauterinesysteminatypicalhyperplasiaandearlystageendometrialcancer
AT mcveyrhonaj baselineserumhe4butnottissuehe4expressionpredictsresponsetothelevonorgestrelreleasingintrauterinesysteminatypicalhyperplasiaandearlystageendometrialcancer
AT crosbieemmaj baselineserumhe4butnottissuehe4expressionpredictsresponsetothelevonorgestrelreleasingintrauterinesysteminatypicalhyperplasiaandearlystageendometrialcancer